Compounds > n'-cyano-n-(3-pyridyl)-n''-(t-butyl)guanidine
Page last updated: 2024-12-06

n'-cyano-n-(3-pyridyl)-n''-(t-butyl)guanidine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

N'-cyano-N-(3-pyridyl)-N''-(t-butyl)guanidine: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID43344
CHEMBL ID75020
SCHEMBL ID6369800
SCHEMBL ID9463611
MeSH IDM0163731

Synonyms (16)

Synonym
CHEMBL75020
p 1060
guanidine, n-cyano-n'-(1,1-dimethylethyl)-n''-3-pyridinyl-
brn 0479173
1-tert-butyl-2-cyano-3-(3-pyridyl)guanidine
guanidine, 1-tert-butyl-2-cyano-3-(3-pyridyl)-
p-1060
n'-cyano-n-(3-pyridyl)-n''-(t-butyl)guanidine
60559-94-6
SCHEMBL6369800
TXXOFXVEUPZZHB-UHFFFAOYSA-N
n-tert-butyl-n-cyano-n'-3-pyridylguanidine
SCHEMBL9463611
DTXSID80209332
p1-060
cgp 14877; p 1060 (pharmaceutical)
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (27)

Assay IDTitleYearJournalArticle
AID1148556Hypotensive activity in spontaneously hypertensive Wistar-Okamoto rat assessed as maximum change in mean blood pressure at 0.05 mg/kg, po relative to control1978Journal of medicinal chemistry, Aug, Volume: 21, Issue:8
Synthesis and hypotensive activity of N-alkyl-N"-cyano-N'-pyridylguanidines.
AID1148550Hypotensive activity in po dosed spontaneously hypertensive Wistar-Okamoto rat assessed as dose required to cause 30 mmHg fall of blood pressure administered for 5 days1978Journal of medicinal chemistry, Aug, Volume: 21, Issue:8
Synthesis and hypotensive activity of N-alkyl-N"-cyano-N'-pyridylguanidines.
AID1148599Vasodilatory activity in conscious normotensive dog assessed as cardiac output at 0.25 mg/kg, po by thermodilution method1978Journal of medicinal chemistry, Aug, Volume: 21, Issue:8
Synthesis and hypotensive activity of N-alkyl-N"-cyano-N'-pyridylguanidines.
AID1148549Toxicity in po dosed mouse assessed as mortality after 7 days1978Journal of medicinal chemistry, Aug, Volume: 21, Issue:8
Synthesis and hypotensive activity of N-alkyl-N"-cyano-N'-pyridylguanidines.
AID1148564Hypotensive activity in spontaneously hypertensive Wistar-Okamoto rat assessed as time required for persistence of hypotensive effect at 0.01 mg/kg, po1978Journal of medicinal chemistry, Aug, Volume: 21, Issue:8
Synthesis and hypotensive activity of N-alkyl-N"-cyano-N'-pyridylguanidines.
AID1148582Hypotensive activity in conscious renal hypertensive dog assessed as time required for persistence of hypotensive effect at 0.05 mg/kg, po measured for 8 hrs1978Journal of medicinal chemistry, Aug, Volume: 21, Issue:8
Synthesis and hypotensive activity of N-alkyl-N"-cyano-N'-pyridylguanidines.
AID1148591Vasodilatory activity in conscious normotensive dog assessed as change in blood pressure at 0.25 mg/kg, po1978Journal of medicinal chemistry, Aug, Volume: 21, Issue:8
Synthesis and hypotensive activity of N-alkyl-N"-cyano-N'-pyridylguanidines.
AID190149The hypotensive activity expressed as rating of therapeutic index (MED/LD50 <1/200).1980Journal of medicinal chemistry, Jan, Volume: 23, Issue:1
Adaptive least-squares method applied to structure--activity correlation of hypotensive N-alkyl-N''-cyano-N'-pyridylguanidines.
AID1148575Hypotensive activity in conscious renal hypertensive dog assessed as maximum change in mean blood pressure at 0.25 mg/kg, po measured for 8 hrs relative to control1978Journal of medicinal chemistry, Aug, Volume: 21, Issue:8
Synthesis and hypotensive activity of N-alkyl-N"-cyano-N'-pyridylguanidines.
AID1148574Hypotensive activity in conscious renal hypertensive dog assessed as maximum change in mean blood pressure at 0.1 mg/kg, po measured for 8 hrs relative to control1978Journal of medicinal chemistry, Aug, Volume: 21, Issue:8
Synthesis and hypotensive activity of N-alkyl-N"-cyano-N'-pyridylguanidines.
AID1148583Hypotensive activity in conscious renal hypertensive dog assessed as time required for persistence of hypotensive effect at 0.1 mg/kg, po measured for 8 hrs1978Journal of medicinal chemistry, Aug, Volume: 21, Issue:8
Synthesis and hypotensive activity of N-alkyl-N"-cyano-N'-pyridylguanidines.
AID1148557Hypotensive activity in spontaneously hypertensive Wistar-Okamoto rat assessed as maximum change in mean blood pressure at 0.1 mg/kg, po relative to control1978Journal of medicinal chemistry, Aug, Volume: 21, Issue:8
Synthesis and hypotensive activity of N-alkyl-N"-cyano-N'-pyridylguanidines.
AID197525Concentration required to cause 50% inhibition of spontaneous activity in rat portal vein1992Journal of medicinal chemistry, Jun-12, Volume: 35, Issue:12
Structure-activity studies of potassium channel opening in pinacidil-type cyanoguanidines, nitroethenediamines, thioureas, and ureas.
AID1148565Hypotensive activity in spontaneously hypertensive Wistar-Okamoto rat assessed as time required for persistence of hypotensive effect at 0.05 mg/kg, po1978Journal of medicinal chemistry, Aug, Volume: 21, Issue:8
Synthesis and hypotensive activity of N-alkyl-N"-cyano-N'-pyridylguanidines.
AID1148566Hypotensive activity in spontaneously hypertensive Wistar-Okamoto rat assessed as time required for persistence of hypotensive effect at 0.1 mg/kg, po1978Journal of medicinal chemistry, Aug, Volume: 21, Issue:8
Synthesis and hypotensive activity of N-alkyl-N"-cyano-N'-pyridylguanidines.
AID1148551Toxicity in po dosed Sprague-Dawley rat assessed as mortality after 7 days1978Journal of medicinal chemistry, Aug, Volume: 21, Issue:8
Synthesis and hypotensive activity of N-alkyl-N"-cyano-N'-pyridylguanidines.
AID1148603Vasodilatory activity in conscious normotensive dog assessed as total peripheral resistance at 0.25 mg/kg, po1978Journal of medicinal chemistry, Aug, Volume: 21, Issue:8
Synthesis and hypotensive activity of N-alkyl-N"-cyano-N'-pyridylguanidines.
AID1148589Hypotensive activity in po dosed spontaneously hypertensive Wistar-Okamoto rat relative to guancydine1978Journal of medicinal chemistry, Aug, Volume: 21, Issue:8
Synthesis and hypotensive activity of N-alkyl-N"-cyano-N'-pyridylguanidines.
AID1148607Toxicity in rat assessed as change in cardiac noradrenaline level at 0.1 mg/kg1978Journal of medicinal chemistry, Aug, Volume: 21, Issue:8
Synthesis and hypotensive activity of N-alkyl-N"-cyano-N'-pyridylguanidines.
AID1148555Hypotensive activity in spontaneously hypertensive Wistar-Okamoto rat assessed as maximum change in mean blood pressure at 0.01 mg/kg, po relative to control1978Journal of medicinal chemistry, Aug, Volume: 21, Issue:8
Synthesis and hypotensive activity of N-alkyl-N"-cyano-N'-pyridylguanidines.
AID197347Concentration required to cause 15% increase in [86Rb+] efflux from rat portal vein.1992Journal of medicinal chemistry, Jun-12, Volume: 35, Issue:12
Structure-activity studies of potassium channel opening in pinacidil-type cyanoguanidines, nitroethenediamines, thioureas, and ureas.
AID1148584Hypotensive activity in conscious renal hypertensive dog assessed as time required for persistence of hypotensive effect at 0.25 mg/kg, po measured for 8 hrs1978Journal of medicinal chemistry, Aug, Volume: 21, Issue:8
Synthesis and hypotensive activity of N-alkyl-N"-cyano-N'-pyridylguanidines.
AID1148573Hypotensive activity in conscious renal hypertensive dog assessed as maximum change in mean blood pressure at 0.05 mg/kg, po measured for 8 hrs relative to control1978Journal of medicinal chemistry, Aug, Volume: 21, Issue:8
Synthesis and hypotensive activity of N-alkyl-N"-cyano-N'-pyridylguanidines.
AID1148590Hypotensive activity in decerebrated cat1978Journal of medicinal chemistry, Aug, Volume: 21, Issue:8
Synthesis and hypotensive activity of N-alkyl-N"-cyano-N'-pyridylguanidines.
AID1148611Toxicity in rat assessed as effect on contraction of nictitating membranes by preganglionic stimulation1978Journal of medicinal chemistry, Aug, Volume: 21, Issue:8
Synthesis and hypotensive activity of N-alkyl-N"-cyano-N'-pyridylguanidines.
AID1148609Toxicity in rat assessed as change in cardiac noradrenaline level at 0.1 mg/kg for 5 days1978Journal of medicinal chemistry, Aug, Volume: 21, Issue:8
Synthesis and hypotensive activity of N-alkyl-N"-cyano-N'-pyridylguanidines.
AID1148595Vasodilatory activity in conscious normotensive dog assessed as change in heart rate at 0.25 mg/kg, po1978Journal of medicinal chemistry, Aug, Volume: 21, Issue:8
Synthesis and hypotensive activity of N-alkyl-N"-cyano-N'-pyridylguanidines.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (17)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903 (17.65)18.7374
1990's12 (70.59)18.2507
2000's2 (11.76)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.82

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.82 (24.57)
Research Supply Index2.89 (2.92)
Research Growth Index4.71 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.82)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other17 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
chlorine
chloride : A halide anion formed when chlorine picks up an electron to form an an anion.		1.9810halide anion;
monoatomic chlorine		cofactor;
Escherichia coli metabolite;
human metabolite
histamine
[no description available]		1.9710aralkylamino compound;
imidazoles		human metabolite;
mouse metabolite;
neurotransmitter
caffeine
[no description available]		1.9810purine alkaloid;
trimethylxanthine		adenosine A2A receptor antagonist;
adenosine receptor antagonist;
adjuvant;
central nervous system stimulant;
diuretic;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor;
EC 3.1.4.* (phosphoric diester hydrolase) inhibitor;
environmental contaminant;
food additive;
fungal metabolite;
geroprotector;
human blood serum metabolite;
mouse metabolite;
mutagen;
plant metabolite;
psychotropic drug;
ryanodine receptor agonist;
xenobiotic
verapamil
Verapamil: A calcium channel blocker that is a class IV anti-arrhythmia agent.. verapamil : A racemate comprising equimolar amounts of dexverapamil and (S)-verapamil. An L-type calcium channel blocker of the phenylalkylamine class, it is used (particularly as the hydrochloride salt) in the treatment of hypertension, angina pectoris and cardiac arrhythmia, and as a preventive medication for migraine.. 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile : A tertiary amino compound that is 3,4-dimethoxyphenylethylamine in which the hydrogens attached to the nitrogen are replaced by a methyl group and a 4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl group.		1.9810aromatic ether;
nitrile;
polyether;
tertiary amino compound
glyburide
Glyburide: An antidiabetic sulfonylurea derivative with actions like those of chlorpropamide. glyburide : An N-sulfonylurea that is acetohexamide in which the acetyl group is replaced by a 2-(5-chloro-2-methoxybenzamido)ethyl group.		3.3770monochlorobenzenes;
N-sulfonylurea		anti-arrhythmia drug;
EC 2.7.1.33 (pantothenate kinase) inhibitor;
EC 3.6.3.49 (channel-conductance-controlling ATPase) inhibitor;
hypoglycemic agent
hydralazine
Hydralazine: A direct-acting vasodilator that is used as an antihypertensive agent.. hydralazine : The 1-hydrazino derivative of phthalazine; a direct-acting vasodilator that is used as an antihypertensive agent.		1.9510azaarene;
hydrazines;
ortho-fused heteroarene;
phthalazines		antihypertensive agent;
vasodilator agent
nifedipine
Nifedipine: A potent vasodilator agent with calcium antagonistic action. It is a useful anti-anginal agent that also lowers blood pressure.		1.9810C-nitro compound;
dihydropyridine;
methyl ester		calcium channel blocker;
human metabolite;
tocolytic agent;
vasodilator agent
pinacidil
Pinacidil: A guanidine that opens POTASSIUM CHANNELS producing direct peripheral vasodilatation of the ARTERIOLES. It reduces BLOOD PRESSURE and peripheral resistance and produces fluid retention. (Martindale The Extra Pharmacopoeia, 31st ed)		3.5890pyridines
potassium chloride
Potassium Chloride: A white crystal or crystalline powder used in BUFFERS; FERTILIZERS; and EXPLOSIVES. It can be used to replenish ELECTROLYTES and restore WATER-ELECTROLYTE BALANCE in treating HYPOKALEMIA.. potassium chloride : A metal chloride salt with a K(+) counterion.		1.9810inorganic chloride;
inorganic potassium salt;
potassium salt		fertilizer
phentolamine
Phentolamine: A nonselective alpha-adrenergic antagonist. It is used in the treatment of hypertension and hypertensive emergencies, pheochromocytoma, vasospasm of RAYNAUD DISEASE and frostbite, clonidine withdrawal syndrome, impotence, and peripheral vascular disease.. phentolamine : A substituted aniline that is 3-aminophenol in which the hydrogens of the amino group are replaced by 4-methylphenyl and 4,5-dihydro-1H-imidazol-2-ylmethyl groups respectively. An alpha-adrenergic antagonist, it is used for the treatment of hypertension.		1.9810imidazoles;
phenols;
substituted aniline;
tertiary amino compound		alpha-adrenergic antagonist;
vasodilator agent
pyrroles
1H-pyrrole : A tautomer of pyrrole that has the double bonds at positions 2 and 4.. pyrrole : A five-membered monocyclic heteroarene comprising one NH and four CH units which forms the parent compound of the pyrrole group of compounds. Its five-membered ring structure has three tautomers. A 'closed class'.. azole : Any monocyclic heteroarene consisting of a five-membered ring containing nitrogen. Azoles can also contain one or more other non-carbon atoms, such as nitrogen, sulfur or oxygen.		3.2360pyrrole;
secondary amine
potassium cyanide
[no description available]		2.0110cyanide salt;
one-carbon compound;
potassium salt		EC 1.15.1.1 (superoxide dismutase) inhibitor;
EC 1.9.3.1 (cytochrome c oxidase) inhibitor;
neurotoxin
cyclopentane
Cyclopentanes: A group of alicyclic hydrocarbons with the general formula R-C5H9.. cyclopentanes : Cyclopentane and its derivatives formed by substitution.		2.4320cycloalkane;
cyclopentanes;
volatile organic compound		non-polar solvent
tetradecanoylphorbol acetate
Tetradecanoylphorbol Acetate: A phorbol ester found in CROTON OIL with very effective tumor promoting activity. It stimulates the synthesis of both DNA and RNA.. phorbol ester : Esters of phorbol, originally found in croton oil (from Croton tiglium, of the family Euphorbiaceae). A number of phorbol esters possess activity as tumour promoters and activate the mechanisms associated with cell growth. Some of these are used in experiments as activators of protein kinase C.. phorbol 13-acetate 12-myristate : A phorbol ester that is phorbol in which the hydroxy groups at the cyclopropane ring juction (position 13) and the adjacent carbon (position 12) have been converted into the corresponding acetate and myristate esters. It is a major active constituent of the seed oil of Croton tiglium. It has been used as a tumour promoting agent for skin carcinogenesis in rodents and is associated with increased cell proliferation of malignant cells. However its function is controversial since a decrease in cell proliferation has also been observed in several cancer cell types.		1.9810acetate ester;
diester;
phorbol ester;
tertiary alpha-hydroxy ketone;
tetradecanoate ester		antineoplastic agent;
apoptosis inducer;
carcinogenic agent;
mitogen;
plant metabolite;
protein kinase C agonist;
reactive oxygen species generator
n-cyano-n'-(1,1-dimethylpropyl)-n''-(3-pyridinyl)guanidine
N-cyano-N'-(1,1-dimethylpropyl)-N''-(3-pyridinyl)guanidine: potassium channel opener		2.6530pyridines
3-pyridyl pinacidil
3-pyridyl pinacidil: RN refers to cpd without isomeric designation		2.6530
rubidium chloride
rubidium chloride : An inorganic chloride composed of rubidium and chloride ions in a 1:1 ratio.		1.9810inorganic chloride;
rubidium molecular entity		antidepressant;
biomarker
pinacidil pyridine n-oxide
pinacidil pyridine N-oxide: metabolite of pinacidil		1.9710
cromakalim
Cromakalim: A potassium-channel opening vasodilator that has been investigated in the management of hypertension. It has also been tried in patients with asthma. (Martindale, The Extra Pharmacopoeia, 30th ed, p352)		3.3770
p-methoxy-n-methylphenethylamine
p-Methoxy-N-methylphenethylamine: A potent mast cell degranulator. It is involved in histamine release.. N,O-dimethyltyramine : A secondary amino compound that is tyramine in which the hydrogen of the phenolic hydroxy group has been replaced by a methyl group.		2.0510aromatic ether;
secondary amino compound		metabolite
sdz pco 400
SDZ PCO 400: a potassium channel opening drug		2.43201-benzopyran
aprikalim
[no description available]		2.6730
dinoprost
Dinoprost: A naturally occurring prostaglandin that has oxytocic, luteolytic, and abortifacient activities. Due to its vasocontractile properties, the compound has a variety of other biological actions.. prostaglandin F2alpha : A prostaglandins Falpha that is prosta-5,13-dien-1-oic acid substituted by hydroxy groups at positions 9, 11 and 15. It is a naturally occurring prostaglandin used to induce labor.		1.9710monocarboxylic acid;
prostaglandins Falpha		human metabolite;
mouse metabolite
rubidium
Rubidium: An element that is an alkali metal. It has an atomic symbol Rb, atomic number 37, and atomic weight 85.47. It is used as a chemical reagent and in the manufacture of photoelectric cells.		2.3920alkali metal atom
charybdotoxin
[no description available]		1.9810
ConditionIndicatedRelationship StrengthStudiesTrials
Blood Pressure, High
[description not available]		01.9510
Hypertension
Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more.		01.9510
Muscle Contraction
A process leading to shortening and/or development of tension in muscle tissue. Muscle contraction occurs by a sliding filament mechanism whereby actin filaments slide inward among the myosin filaments.		02.6730
Sensitivity and Specificity
Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)		01.9810
Adenoma, beta-Cell
[description not available]		01.9810
Cancer of Pancreas
[description not available]		01.9810
Insulinoma
A benign tumor of the PANCREATIC BETA CELLS. Insulinoma secretes excess INSULIN resulting in HYPOGLYCEMIA.		01.9810
Pancreatic Neoplasms
Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).		01.9810
Muscle Relaxation
That phase of a muscle twitch during which a muscle returns to a resting position.		01.9710